Announcement on Adjusting the Development Strategy of BAT3306 (Pembrolizumab)
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Adjusting the Development Strategy of BAT3306 (Pembrolizumab)
Filed with SSE · · 2 pages · Chinese
Release
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Completing the Term Change and Election of the Board of Directors and Appointment of Senior Management Members, Securities Affairs Representatives, and Head of Internal Audit
- Report for Q1 2025
- Announcement on Share Reduction Plan for Shareholders
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT7111 for Injection
- Announcement on Election of Employee Representative Director for the Third Board of Directors
Later from Bio-Thera Solutions
- Announcement on FDA Approval for BAT2206 (Ustekinumab) Injection in the United States
- Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
- Bio-Thera Solutions Receives Positive CHMP Opinion for USYMRO®(ustekinumab), a Biosimilar Referencing Stelara®
- Announcement on Voluntary Disclosure of Signing Authorization License and Production, Supply and Commercialization Agreement with SteinCares for BAT2406 (Dupilumab) Injection
- Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions